ReviewFrontiers in microbiology2025
New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Impact of vaginal microbiota on the clinical efficacy and long-term recurrence of ketoconazole suppositories in treating severe vulvovaginal candidiasis: a secondary analysis of a multicentre randomised trial.Frontiers in cellular and infection microbiology · 2025Trial
- RL-QN15 accelerates vaginal mucosal repair by regulating inflammatory, autophagic, and apoptotic responses.Biochemistry and biophysics reports · 2026Article
- Intravaginal Formulation Strategies for Vaginal Disorders: Optimizing Phytochemical and Biological Preparations-A Review.Molecules (Basel, Switzerland) · 2026Review
- Vaginal microbiomes and their pertinent social context: a microbial ecological review proffering AMR-STI acquisition and emergence.Biology of sex differences · 2026Review
- Differential Virulence of VaginalJournal of fungi (Basel, Switzerland) · 2026Article
- The Gut-Vagina Axis.Microorganisms · 2026Review
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Elevated vaginal heparan sulfate correlates with impaired neutrophil killing ofInfection and immunity · 2026Article
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Diagnostic performance of deep learning-based vaginal microecological morphology assessment for bacterial vaginosis and vulvovaginal candidiasis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower genital tract infections, particularly vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV), are among the most prevalent infections in women worldwide, especially those of reproductive age. These conditions not only cause significant clinical symptoms but also severely impact women's quality of life and mental health. Despite extensive research on the pathogens involved, substantial gaps remain in understanding the vaginal immune response and the complexity of the vaginal ecosystem, which is largely shaped by a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.